Showing posts with label Research integrity. Show all posts
Showing posts with label Research integrity. Show all posts

Tuesday, May 14, 2024

Video on the Bad Science That Keeps Smokers Smoking, and Dying

 

I recently participated in a panel discussion about tobacco harm reduction (THR) at the Tobacco Merchants Association meeting.  While assembling my powerpoint presentation, I recalled that I presented to this group 18 years ago, in 2006, what was likely their first introduction to THR. 

To view my 10-minute primer on bad science – then and now – watch this video, starting at the 26-minute mark.  I discuss the genesis of the myth that smokeless dip and chew products present a high risk for mouth cancer (discussed extensively in this blog by searching for “Winn”), and my THR team’s attempts to correct fatally flawed vaping research articles.    

I’m happy to provide the slides upon request.    

Wednesday, August 18, 2021

Stanton Glantz’s Tainted Science: The Rest of the Story

 

Journalist Marc Gunther recently authored articles for Undark (here) and Medium (here) about “The tainted science of Stanton Glantz.” 

It is evident that Gunther interviewed or corresponded with numerous Glantz research critics. Gunther’s sources include the author of this blog, who provided extensive documentation of Glantz’s questionable work. However, since Gunther fails to tell the whole story, I will provide the rest of it here.

Fake Heart Attacks

The most important items in Gunther’s articles are his descriptions of Glantz’s flawed heart attack study that appeared in the Journal of the American Heart Association – a work that was retracted eight months after its publication in June 2019. Gunther described that study and its repercussions in his Undark article as follows:

“…when describing the second study, published in 2019 in the Journal of the American Heart Association, Glantz said it provided ‘more evidence that e-cigs cause heart attacks.’… Critics pounced on what they called glaring flaws in the analyses. Some of the e-cigarette users had previously smoked, for example, muddying the correlation. Brad Rodu, a University of Louisville professor who has numerous and longstanding connections to the tobacco industry, dug into the raw data and found that at least 11 of the 38 heart-attack victims cited in the Journal of the American Heart Association study had suffered their heart attacks before they started vaping — some as many as 10 years before. Glantz was made aware of the temporality problem before publication because it was raised by a peer reviewer, the journal’s editor subsequently realized.

 

“Sixteen tobacco researchers wrote to the journal editor asking for a retraction, and the Journal of the American Heart Association ultimately did just that — something it has done only a handful of times in its history. Its editor, though, was careful to state in a letter to Glantz that ‘the retraction notice is intentionally absent of any language suggesting scientific misconduct.’

 

“Andrew Gelman, a professor of statistics at Columbia University who followed the controversy on his blog, was unimpressed with Glantz’s response to the retraction, calling it ‘anti-scientific.’ He wrote: ‘If someone points out an error in your work, you should correct the error and thank the person. Not attack and try to salvage your position with procedural arguments.’”  

Gunther is correct: I had discovered that Glantz deliberately deceived the journal’s editors and readers by counting heart attacks before people had vaped. My comments on this appeared in a USA Today article by Jayne O’Donnell on July 17, 2019. O’Donnell wrote, “However, when Rodu obtained the federal data, he found the majority of the 38 patients in the study who had heart attacks had them before they started vaping — by an average of 10 years earlier. In his letter to the editors [dated July 11, 2019], Rodu called Glantz's findings ‘false and invalid…Their analysis was an indefensible breach of any reasonable standard for research on association or causation…We urge you to take appropriate action on this article, including retraction.’” (emphasis added) 

As noted, I publicly called for a retraction on July 17, 2019. But Gunther credited the retraction to “sixteen tobacco researchers,” linking to a letter they wrote to the journal editor on January 20, 2020. In the USA Today article I also called for a federal investigation, and I followed up a year later with a full analysis of the fraudulent findings, which was published in the journal Addiction (discussed here). 

Gunther correctly cited influential statistician Andrew Gelman. I had corresponded with Gelman in 2018 about Glantz’s woefully defective Pediatrics study, which also elicited a retraction demand from me (here, here, here and here). Gelman’s account of our correspondence is here (see Episode 1). Three months before Pediatrics retracted the study, Gelman ran the analysis of it that I had recommended to researchers world-wide in November 2019. 

In his Medium article, Gunther identifies a group of “respected veterans of the anti-smoking movement (Steven Schroeder, Ken Warner, David Abrams, Raymond Niaura and [Michael] Siegel),” and he provided links to their university profiles. Later in the article, he attributes the JAHA retraction to “other scholars”, followed by a comment from me, who he characterizes again with “whose work has been supported by the tobacco industry.” Gunther makes no mention of my 27 years of research into tobacco harm reduction, and provides no link to my university webpage profiles (here and here). 

Perhaps Gunther was influenced by the established (anti-) tobacco research and policy community, some of whom switched to support safer products only after e-cigarettes became popular. Gunther writes that they tolerated Glantz’s defective studies.

“‘Stan has always been an advocate and ideologue willing to twist the science,’ says David Abrams, a New York University professor and veteran tobacco researcher. He says that some scientists ignored flaws in his work when Glantz focused on combustible tobacco because they, too, strongly opposed smoking. ‘Frankly, none of us cared if he was a little bit sloppy with his research because the ends justified the means,’ Abrams says.” 

I never tolerated Glantz’s flaws and sloppy research, and I published numerous critical comments in journal forums and in my blog starting in 2004. Gunther mentioned two examples but did not acknowledge the active role I played in correcting Glantz’s record.

Fake Teen Gateway

Gunther’s biggest error is his description of Glantz’s “2018 study in Pediatrics, [which] also claimed that e-cigarette usage encourages more young people to smoke…a gateway effect, but the alleged link between vaping and smoking disappeared when other teen behaviors, such as using marijuana, were taken into account.”

I replicated that study’s analysis and proved that Glantz’s team had fabricated false results, which I described in detail in a letter to the editors that included a call for retraction (here). That led to an extended exchange with Glantz and Pediatrics editors, with the latter going to great lengths to defend the flawed research (here, here and here).   

The “Helena Miracle”

Gunther noted the “Helena miracle”, in which Glantz credited public smoking bans for a decrease in hospital admissions for heart attacks in the small Montana town. Gunther wrote, “The small sample size in Helena — four cases per month during the ban, compared to seven beforehand — should have raised red flags; random fluctuations could have explained the drop in hospital admissions.” As I had told Gunther, bright red flags were raised by me in comments to the BMJ in 2004 (here) and 2006 (here). My analysis showed that the number of hospital admissions in Helena and other miracle localities was so small that “the relevant question is whether [the Helena] report involves anything more than random variation.” (here)

I attempted to reproduce Glantz’s tiny city reports by conducting an analysis using state-wide data. My study, published in 2011 (discussed here), was subsequently referenced by other researchers (here). I found that rates of death due to heart attacks in states with smoking bans were no different than those in states with no ban, and that heart attacks had been declining everywhere for years. The last point is something Glantz never took into account; in fact, he freeloaded his second-hand smoke heart-attack results on the decades-long downward trend in heart attack rates.

Fake “Softening” of the Smoking Population

In 2015, Glantz proclaimed in Tobacco Control that there is no public health basis for advising smokers that smokeless tobacco and e-cigarettes are safer cigarette alternatives, because the smoking population in the U.S. was “softening”, i.e., becoming more likely to quit (abstract here). Once again, I found that his analysis was seriously flawed, as he failed to consider a number of other significant factors. My research group recreated his analysis and took into account the missing factors; we found that Glantz’s “softening” disappeared.  We published our study in the journal Addiction (discussed here). 

Other Glantz Publication Problems

Glantz Redefined Youth Smoking, 2014  https://rodutobaccotruth.blogspot.com/2014/04/ucsf-redefines-youth-smoking-journals.html

Glantz Falsely Linked E-Cigarettes to Smoking, 2014 https://rodutobaccotruth.blogspot.com/2014/03/ucsf-study-falsely-links-e-cigarettes.html

Glantz Misrepresented IQOS Studies to the FDA, 2017 https://rodutobaccotruth.blogspot.com/2017/11/smoke-but-no-fire-iqos-opponent.html

Glantz Used Complicated Models to Try to Change NYTS Data, 2017 https://rodutobaccotruth.blogspot.com/2017/02/complicated-models-cant-alter-data.html

https://rodutobaccotruth.blogspot.com/2017/02/complicated-models-cant-alter-data-part.html

Glantz’s Failed Attempt to Link Teen Smoking to Cinematic Smoking, 2017 https://rodutobaccotruth.blogspot.com/2017/08/teen-smoking-unconnected-to-cinematic_30.html

Another E-Cigarette Gateway Claim by Glantz Based on Tiny Numbers, 2018 https://rodutobaccotruth.blogspot.com/2018/04/another-uc-san-francisco-e-cigarette.html

Trace Toxins in Teens Improperly Blamed on E-Cigarettes, 2018 https://rodutobaccotruth.blogspot.com/2018/03/beyond-headlines-trace-toxins-present.html

Federal Funds Misspent on Glantz’s Research, 2020 https://rodutobaccotruth.blogspot.com/2020/02/federal-funds-misspent-on-anti-vaping.html

 

Since 2006, the National Institutes of Health has funneled $51 million to Glantz at the University of California San Francisco. In addition to the flawed heart attack work, which may be viewed as research misconduct using federal funds, he published 300 other articles. I list above only the worst offenders and note my attempts to correct them.

 

 

Wednesday, July 7, 2021

The British Medical Journal Falsely Claimed “Harm Reduction Advocates and the Tobacco Industry Capitalised on the Pandemic to Promote Nicotine”

 

The British Medical Journal (BMJ) on June 2 published an article, titled “Research Integrity”, authored by two investigative journalists.  Aping the position of the World Health Organization, they accuse harm reduction advocates and the tobacco industry of undermining decades of tobacco control.  The BMJ notes that the article was “externally peer reviewed.” 

The journal has a rapid-response comment system that is managed by the editors.  I submitted a comment on June 9, detailing specific scientific problems with the article’s content.  It was not published, so I present it here. 

_________________________________________

 

The Editor 

British Medical Journal 

Dear Sir,

The recent article by Stéphane Horel and Ties Keyzer claimed that “the tobacco industry capitalised on the [covid 19] pandemic to promote nicotine” when “two preprints published in quick succession in April 2020… made headlines worldwide. They were also picked up by libertarian media outlets… The World Health Organization worried that decades of tobacco control could be undermined.” (Reference 1) 

Horel and Keyzer then stated: “It has since been roundly disproved that smoking protects against covid-19. Among other studies (2,3,4) the OpenSafely dataset, based on the primary care records of 17.3 million adults in the UK, found that smoking, when adjusted for age and sex, was associated with a 14% increased chance of covid-19 related death (5).”

Horel and Keyzer implied that the four research citations (assigned different reference numbers here) “roundly disproved that smoking protects against covid-19.”  It is ironic that the article by Horel and Keyzer was published in BMJ under the topic of “Research Integrity,” because their own research may not have reached the level readers deserve in a quality medical journal.  In fact, a close look at their four studies, and others that they omit, roundly disproves their disproval claim. 

Three of the four studies (2,3,4) cited by Horel and Keyzer report positive associations, but they need further clarification.  For example, the first study did not employ rigorous diagnostic criteria: study participants used an app launched via radio, TV and social media in the UK to report covid-19 “symptoms” and “whether they thought that they already had COVID” (2).  The second study found that smokers were 3.5 times more likely to have confirmed covid-19 (95% confidence interval, CI = 2.4 – 6.1) than never smokers, but this was only true for participants with low education (3).  However, the risk for highly educated smokers was not elevated at all.  A longitudinal follow-up study found that current smokers had a slightly, but non statistically significant, elevated odds of confirmed covid-19 (minimally adjusted odds ratio (AOR) = 1.24, CI = 0.85 – 1.24) (4).  Finally, Horel and Keyzer carefully describe the OpenSafely study (5) as evidence, saying that current smoking, “when adjusted for age and sex, was associated with a 14% increased chance of covid-19 related death.”  True enough.  But what they fail to mention is that, when the result was fully adjusted for confounding factors, the effect of current smoking became statistically significantly protective (AOR = 0.89, CI = 0.82 – 0.97).

Horel and Keyzer also failed to accurately cite and acknowledge studies that have shown a protective effect of current smoking on covid-19 (6,7,8).  They mentioned such a study from China but didn’t reference it, which is unfortunate because it was published in the New England Journal of Medicine (6).  They also mentioned and cited a study from France (7), but characterized it only as published quickly and as the origin of media hype. 

Horel and Keyzer completely omitted other studies, such as one involving veterans in the U.S., which found that smokers were much less likely to test positive for covid-19 than nonsmokers (AOR = 0.45, CI = 0.35 – 0.57) (8).  Another omission was a rapid evidence review of 28 observational studies finding that “Current data suggest that smokers in the community appear to be less likely to test positive for SARS-CoV-2 compared with never smokers,” “Across 405 studies, recorded current but not past smoking prevalence was generally lower than national prevalence estimates. Current smokers were at reduced risk of testing positive for SARS-CoV-2 and former smokers were at increased risk of hospitalisation, disease severity and mortality compared with never smokers.” (9)  However, one omission by Horel and Keyzer is especially inexplicable, because the study was published by this journal (BMJ) (10).  In that study smokers were significantly less likely than non-smokers to be diagnosed with COVID-19 and to be admitted to an intensive care unit (ICU), and the latter effect was dose-dependent.  The adjusted hazard ratios for ICU admission was 0.26 (CI = 0.19 – 0.37) for light smokers and 0.07 (CI = 0.01 – 0.47) for heavy smokers.   

In summary, there is substantial evidence that current smoking may be negatively associated with a covid-19 diagnosis and its subsequent course, including death. 

Brad Rodu

 

References

1.  Horel S, Keyzer T.  Covid 19: How harm reduction advocates and the tobacco industry capitalised on the pandemic to promote nicotine.  BMJ 2021. 373 doi: https://doi.org/10.1136/bmj.n1303 (Published 02 June 2021)

2.  Hopkinson NS, Rossi N, El-Sayed Moustafa J, et al.  Current smoking and COVID-19 risk: results from a population symptom app in over 2.4 million people.  Thorax 2021. https://doi:10.1136/thoraxjnl-2020-216422   

3.  Jackson ‍‍SE, Brown J, Shahab ‍‍L, et al.  COVID-19, smoking and inequalities: a study of 53 002 adults in the UK.  Tob Control 2020. https://doi:10.1136/tobaccocontrol-2020-055933  

4.  Holt H, Talaei M, Greenig M, et al. Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK). MedRxiv 2021 [preprint]. https://doi:10.1101/2021.03.27.21254452

5.  Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-6. https://doi:10.1038/s41586-020-2521-4  pmid:32640463

6.  Guan WJ, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 382, 1708–1720.  https://DOI:10.1056/NEJMoa2002032

7. Miyara M, Tubach F, Pourcher V, et al. Low rate of daily active tobacco smoking in patients with symptomatic COVID-19. Qeios. 9 May 2020. https://www.qeios.com/read/WPP19W.4

8. Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 testing, hospital admission, and intensive care among 2,026,227 United States veterans aged 54–75 years. MedRxiv 2020 https://doi.org/10.1101/2020.04.09.20059964.

9.  Simons D, Shahab L, Brown J, et al. The association of smoking status with SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence review with Bayesian meta-analyses (version 11). Qeios 2021. https://doi:10.32388/UJR2AW.13

10.  Hippisley-Cox J, Young D, Coupland C, et al.  Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people.  BMJ Volume 106, Issue 19, 2020 https://heart.bmj.com/content/106/19/1503

 

Competing interests: The author’s research is supported by unrestricted grants from tobacco manufacturers to the University of Louisville and by the Kentucky Research Challenge Trust Fund. The sponsors had no knowledge of this work and therefore had no input or other influence in the design, analysis, interpretation, or in the preparation of and decision to submit the rapid response.